AX9.F : Summary for AKEBIA THERAPEUT.DL-00001 - Yahoo Finance

U.S. Markets closed

Akebia Therapeutics, Inc. (AX9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
7.96+0.19 (+2.43%)
At close: 10:04 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close7.77
Bid7.75 x 30000
Ask8.06 x 30000
Day's Range7.81 - 7.96
52 Week Range6.19 - 11.63
Avg. Volume42
Market Cap292.27M
PE Ratio (TTM)-2.42
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press26 days ago

    Akebia Therapeutics reports 3Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 96 cents per share. Akebia Therapeutics shares have dropped 34 percent since the beginning of the year. In the final minutes of trading ...

  • Benzinga2 months ago

    Akebia Price Target Lowered, Still A Buy At Brean

    Brean Capital assumes coverage of Akebia Therapeutics Inc (NASDAQ: AKBA ) with a Buy rating, with a lowered target price of $18, citing potential success of its anemia drug. The company's lead product ...

  • Calculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals
    Insider Monkey4 months ago

    Calculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals

    Akebia Therapeutics Inc (NASDAQ:AKBA) just gave word of the initiation of its pivotal trial in a second indication for its lead renal anemia candidate, Vadadustat. The company already has one trial running, which kicked off late 2015, in non-dialysis dependent patients with anemia related to chronic kidney disease. This second indication is for the same […]